Prenatal panel screening considerations for non-neuronopathic Gaucher disease in the Ashkenazi-Jewish population

Israel Medical Association Journal

Volumn 8, Issue 5, 2006, Pages 347-350

  Kannai, Ruth ^a,b,e   Chertok, Ilana R ^c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NONE   (Israel)

Author keywords

Non neuronopathic Gaucher disease; Panel multi test kit; Prenatal screening

Indexed keywords

IMIGLUCERASE;

AWARENESS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CENTER; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; INFORMED CONSENT; INTERNET; ISRAEL; JEW; MASS SCREENING; MEDICAL DECISION MAKING; MEDICAL ETHICS; MORBIDITY; PANEL STUDY; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PROGNOSIS; RECESSIVE INHERITANCE; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST;

ABORTION, EUGENIC; FEMALE; GAUCHER DISEASE; GENETIC SCREENING; HUMANS; JEWS; PREGNANCY; PRENATAL DIAGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 33744478375     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Charrow J. Ashkenazi Jewish genetic disorders. Familial Cancer 2004;3:201-6.
2. NIH Technology Assessment Conference. Gaucher Disease. Current issues in diagnosis and treatment. JAMA 1996;275(7):548-53.
3. American College of Obstetricians and Gynecologists (ACOG), Committee on Genetics. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2004;104:425-8.
4. Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: Presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004;163:58-66.
5. Whitfield PD, Nelson P, Sharp PC, et al. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 2002;75:46-55.
6. Vallance H, Ford J. Carrier testing for autosomal-recessive disorders. Crit Rev Clin Lab Sci 2003;40:473-97.
7. Zimran A, Zaizov R, Zlotogora J. Large scale screening for Gaucher's disease in Israel - a position paper by the National Gaucher Committee of the Ministry of Health. Harefuah 1997;133:107-8 (Hebrew).
8. Leib JR, Gollust SE, Hull SC, Wilfond BS. Carrier screening panels for Ashkenazi Jews: Is more better? Genet Med 2005;7:185-90.
9. Eng CM, Schecter C, Robinowitz J. Prenatal genetic carrier testing using triple disease screening. JAMA 1997;278(15):1268-72.
10. Kronn D, Jansen V, Ostrer H. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med 1998;158(7):777-81.
11. http://www.health.gov.il/download/pages/new_asor1.pdf
12. Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A. Asymptomatic Gaucher disease implications for large-scale screening. Genet Test 1998;2:297-9.
13. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-43.
14. Raz A. "Important to test, important to support": attitudes toward disability rights and prenatal diagnosis among leaders of support groups for genetic disorders in Israel. Soc Sci Med 2004;59(9):1857-66.
15. http://www.clalit.org.il/haemek/Content/Content.asp?CID=11&u=39; http://www.health.gov.il/pages/ default.asp?pageid=863&parentid=854&catid=116&maincat=35
16. http://www.hadassah.org.il/Hadassa/Heb_SubNavBar/Departments/ Medical+departments/Genetics/Hdaf2.htm; http://www.tasmc.org.il/main/ siteNew/index.php?langId=3&page=502&action=sidLink&stId=1182; http://www.almogi-clinics.co.il/articles.asp?n=5
17. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001; 44:297-310.
18. Gross ML. Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel. Theor Med Bioeth 2002;23:151-70.
19. Sagi M. Ethical aspects of genetic screening in Israel. Sci Context 1998;11:419-29.
20. Elstein D, Abrahamov A, Hadas-Halperm I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haemotol 2000;110:488-92.